ClinicalTrials.gg
CompletedNCT05176015Updated Mar 18, 2026

Nystagmus Assessment for Patients Consulting in the Emergency Department for Acute Vertigo

An interventional study of Frenzel Lens and Diagnostic Algorithm in Nystagmus, Acquired and Stroke, Acute, sponsored by CHU de Quebec-Universite Laval. Completed at 5 sites in Canada. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by CHU de Quebec-Universite Laval · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

This pilot study is perfomed to validate and document faisability of the use of Frenzel lens and the use of a diagnostic algorithm for the assessment of a special sign (nystagmus) observe in the eyes of patients consulting in the emergency department (ED) for an acute episode of vertigo/dizziness/imbalance.

Read the detailed description

This pilot study is a randomized controlled trial 2 by 2 design to allocated randomly the Frenzel lens and the diagnostic algorithm. There is no use of sham lens. The usual care opposed to the diagnostic algorithm will be questioned only on the perception of nystagmus by the clinician and the use of repositioning particles technique. The only blinding will be the patients about the use of the algorithm and the outcomes assessor about the use or not of Frenzel lens and the use or not of the diagnostic algorithm.

02

Conditions studied

  • Nystagmus, Acquired
  • Stroke, Acute

Keywords

  • nystagmus
  • stroke
  • neuroimaging
  • cardiovascular disease
  • benign positional paroxystic vertigo
03

In context

Nystagmus, Pathologic

27 studies on the registry are indexed under Nystagmus, Pathologic; 3 are open to participants now.

This study's enrollment of 120 is above the median of 48 across 17 interventional studies indexed under Nystagmus, Pathologic.

Browse Nystagmus, Pathologic studies →

Lead sponsor

CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New episode of acute vertigo/dizziness/imbalance occuring during the 28 last days
  • Must be able to consent.

Exclusion criteria

Exclusion Criteria:

  • No traumatic context before symptoms onset
  • No intoxication context
  • Glycemia ≤ 3,0 mmol/L
  • Only one participation is permitted
  • Not able to speak adequately in French or English.
  • Reachable for 3 month follow-up
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Frenzel Lens with Diagnostic Algorithm

    Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and if present describe its main characteristic. Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging

    Device: Frenzel Lens · Diagnostic Test: Diagnostic Algorithm

  • Experimental
    Frenzel Lens without Diagnostic Algorithm

    Frenzel lens will be applied on patients' eyes during different diagnostic maneuvers to assess if a nystagmus is present and describe its main characteristics. No diagnostic algorithm will be used to interpret nystagmus.

    Device: Frenzel Lens

  • Experimental
    No Frenzel Lens with Diagnostic Algorithm

    Nystagmus assessment in different manoeuvres is performed without the use of Frenzel lens. Without mentioning to patient, the emergency physician will use a diagnostic algorithm inspired from the TiTrATE approach to interpret the nystagmus and propose the need or the irrelevance for neuro-imaging

    Diagnostic Test: Diagnostic Algorithm

  • No intervention
    No Frenzel Lens and No Diagnostic Algorithm

    The emergency physician is performing the assessment of nystagmus and its interpretation as usual. The Frenzel lens and the diagnostic algorithm are not used.

Interventions

  • DeviceFrenzel Lens

    pair of magnifying glasses (+20 dioptres) that are worn by the patient and an illuminating system. On using Frenzel goggles, the nystagmus is better seen as a result of eyes being magnified and inhibition of visual fixation.

  • Diagnostic testDiagnostic Algorithm

    A diagnostic algorithm using the TiTrate approach: continuous, Intermittent, trigger or spontaneous. The diagnostic algorithm use the REDCap software that include different videos to illustrate diagnostic tests and nystagmus types. Different maneuvers: HINTS+ battery, Dix-Hallpike test, Supine Roll test. Different Particle Repositioning Techniques will be proposed according to specific tests: Epley and Gufoni maneuvers. Risk Score is used to assess stroke risk for transient ischaemic attack (TIA): ABCD2 and the Canadian TIA Risk Score

06

What researchers measure

Primary outcomes

  1. Rate of Nystagmus detection per participant

    During eye examination, nystagmus will be characterized according to prominent direction of the fast phase (patients' left, patients' right, up, down, rotational),with their clinical setting or trigger. Overall rate of nystagmus detection by participant. (Rate of typical nystagmus for benign paroxysmal positional vertigo in the Dix-Hallpike maneuver or Supine Head Roll Test. Rate of nystagmus detection in the initial physical exam)

    Time frame: Day 0

Secondary outcomes

  1. Emergency Department Length of stay

    Time spent at the emergency department from triage to time of departure for hospital admission or for home discharge assessed up to 48 hours

    Time frame: Day 0, from triage time to Emergency Department departure (admission or home discharge)

  2. Rate of neuro-imaging per participant

    Any imaging to investigate acute intra-cerebral lesion and/or the neck/brain vascular. anomaly : computed tomography imaging; computed tomography angiogram; magnetic resonance angiography; magnetic resonance imaging, vascular neck ultrasound imaging.

    Time frame: From day 0 to 12 weeks

  3. Rate of acute stroke per participant

    Any acute stroke, hemorrhagic or ischemic, diagnosed by neuro-imaging: computed tomography or magnetic resonance imaging

    Time frame: From day 0 to 12 weeks

  4. Rate of symptomatic central lesion per participant

    Any central lesion diagnosed by computed tomography or magnetic resonance imaging that may be related to the initial presentation of vertigo/dizziness/imbalance

    Time frame: From day 0 to 12 weeks

  5. Rate of specialised consultations for vertigo/dizziness/imbalance per participant

    Any specialised consultations (neurology, ear nose and throat (ENT), cardiology or similar) to investigate the acute vertigo/dizziness/imbalance with the final diagnosis. Sumarisation of final diagnosis.

    Time frame: From day 0 to 12 weeks

  6. Rate of acute vertigo/dizziness/imbalance related hospitalisation per participant

    Admission to hospital directly related to vertigo/dizziness/imbalance may be immediate to initial visit or delayed.

    Time frame: From day 0 to 12 weeks

  7. Rate of subsequent Emergency Department Visit for Vertigo/dizziness/imbalance per participant

    Return visit to the emergency department for vertigo/dizziness/imbalance as chief complaint.

    Time frame: From day 0 t0 12 weeks

  8. Rate of New Atrial Fibrillation

    Atrial fibrillation detected by the initial visit electrocardiogram or by long-term cardiac rhythm monitoring (Holter or loop recorder).

    Time frame: From day 0 to 12 weeks

  9. Rate of New Stroke at 12 weeks

    A stroke free status will be assessed by a validated questionnaire by telephone at tree months and all specialised consultations and neuroimaging will be reviewed for acute stroke diagnosis,

    Time frame: At 12 weeks

  10. Rate of the use of Particles Repositioning Technique

    Once Paroxysmal Positional Vertigo diagnosis is being diagnosed with the Dix-Hallpike test or with the Supine Head Roll test, the use of particles repositioning technique, Epley or Gufoni maneuvers, will be noted with their immediate impact on acute vertigo.

    Time frame: Day 0

  11. Rate of Emergency Department Visit Return for Benign Paroxysmal Positional Vertigo according to Typical Nystagmus

    Rate of Emergency Department Visit Return for Benign Paroxysmal Positional Vertigo according to Typical Nystagmus: direction, duration

    Time frame: From day 0 to 12 weeks

  12. Initial managment self appreciation of patient presenting in the ED for an acute episode of vertigo/dizziness/imbalance

    Simple question answered on a likert scale at the end of the ED encounter. 0% worst, 100% best appreciation.

    Time frame: Day 0

  13. Adverse Events

    Combination of stroke, death, neurosurgery, intervenional neuroradiology, thrombolytic therapy

    Time frame: From day 0 to 12 weeks

07

Study locations

5 sites
  • Centre Hospitalier d'Amqui
    Amqui, Quebec G5J 2K5, Canada
  • Centre Hospitalier de Matane
    Matane, Quebec G4W 2W5, Canada
  • Centre Hospitalier de Montmagny
    Saint Thomas de Montmagny, Quebec G5V 3R8, Canada
  • Hopital St-Georges
    Saint-Georges, Quebec G5Y4T8, Canada
  • Hopital Notre-Dame-de-Fatima
    Ste. Anne de la Pocatière, Quebec G0R 1Z0, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05176015
Responsible party
Pierre La Rochelle (Chief Investigator, CHU de Quebec-Universite Laval) — Principal investigator
First posted
Jan 4, 2022
Start date
Jan 15, 2022
Primary completion
Feb 10, 2025
Completion
Feb 10, 2025
Last update
Mar 18, 2026

Study contacts

Pierre La Rochelle, MD, MSc
principal investigator · Universite Laval

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion